Peer Reviewed
This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.
Megan Alhadeff, PharmD, MBA
Advertisement
Articles by Megan Alhadeff, PharmD, MBA
Advertisement
Latest Updated Articles
A Review of Anti-HER2 Targeted Agents in Non-Breast Solid TumorsFebruary 14th 2024
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
2
What Pharmacists Should Know About Novo Nordisk-Eli Lilly GLP-1 Ad Suit
3
FDA Approves Dolutegravirfor HIV Treatment in Newborns
4
FDA Clears First Continuous Glucose-Ketone Monitor
5